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INTRODUCTION:
Advanced prostate cancer is a common killer in the United States. The American Cancer Society estimates that more than 28,000 men will die of advanced stage prostate cancer in this year alone (1) . Approximately 90% of all cancer deaths are due to metastasis, which is the spread of the cancer to distant sites. Although many cancer mutations have been identified, little is known about what drives cancer to progress and metastasize. Therefore, the creation of novel preclinical models to discover which mutations cause progression and metastasis would be of great value. Here, we describe a novel methodology, based on the piggyBac (PB) transposon, to induce and identify mutations that promote the progression and metastasis of solid tumors, and apply it to the analysis of prostate cancer. We have refined the highly efficient PB transposon system to induce mutations and added a reporter that allows us to visualize tumor development and the spread of cancer cells in live mice. By introducing this mutagenesis system into mice that develop early stage prostate tumors, we will be able to identify mutations that cause prostate tumors to advance and metastasize. Ultimately, we will then validate these identified mutations in human tumor samples. Identifying which mutations are responsible for tumor progression and metastasis will pave the way for understanding and treating advanced stage cancer.
BODY:
Hypothesis: 1. The PB-based somatic mutagenesis will reveal genetic alterations responsible for progression of prostate cancer. 2. The genetic changes identified in mice are relevant for carcinogenesis of human prostate cancer.
Objectives:
1. To establish the first forward genetic model for somatic mutagenesis of prostate tissue.
We have developed a somatic mutagenesis system for cancer gene discovery in the mouse based on the PB transposon. The high efficiency of PB transposition permits screens to be performed using few mutagenic transposons, offering the additional advantage of circumventing high background mutation rates in identifying causative mutations. As a result we have developed a highly efficient, low-copy PB mutagenesis system (PB-SMART) utilizing a sevencopy PB mutator called Luc-PB [mut] 7, which can also monitor mutagenesis by luciferase expression. This system has been described in our recent publication where we demonstrate the utility of the system in whole animal and skin targeted mutagenesis (2, appendix pg. 39). We have also used this system to conduct a low-copy transposon mutagenesis screen for melanoma (appendix, pg.11). Exome sequencing has revealed that somatic mutations in human melanomas greatly exceed those in other cancers, making it a challenge for predicting causative genes from the large collection of mutations. In the attached paper, we demonstrate that low-copy transposon mutagenesis in mice offers a powerful and complementary way to decipher which alterations actually drive human melanoma. Currently, we are utilizing PB-SMART to screen for genes that drive prostate cancer progression as detailed below.
To identify genes whose activation or inactivation may cause progression of prostate cancer.
We began screening in the Nkx3.1 +/-background with the PB-SMART system and are currently aging the mice and observing them for tumor development. Specifically we have crossed
Nkx3.1 +/-mice into the Luc-PB[mut]7/ ACT-Stop-PBase/ PB4-Cre+ background. Currently we
have eight mice in this Nkx3.1 +/-screening group that have surpassed a year of age and none have developed signs of prostate tumor development. Ideally we would like to increase the incidence of tumor formation before a year to enhance our screening efficiency.
We have found that body-wide mutagenesis can be highly effective in inducing cooperating mutations with an organ-specific sensitizing mutation as demonstrated in the melanoma screen (appendix, pg. 11). As a result, we compared the efficiency of transposon mobilization in the anterior prostate with transposase expression restricted by the PB4 promoter (Luc-
PB[mut]7/ACT-Stop-PBase/ PB4-Cre+) versus the ACT promoter (Luc-PB[mut]7/ACT-PBase).
We have found that mutagenesis with ACT-PBase where transposon mobilization occurs in early development rather than in response to androgen from the PB4-CRE results in higher transposition efficiency (9-30 fold) in the anterior prostate ( We have also decided to increase the efficiency of the screen by using a more sensitized genetic background. The tumor suppressor PTEN is inactivated in approximately 40% of human prostate cancer (3, 4) . Mice with prostate-specific deletion of the tumor suppressor Pten develop early benign cancer, prostatic intraepithelial neoplasia (PIN) that can progress to high-grade adenocarcinoma with long latency, but without progression to frank metastasis (5) (6) (7) (8) . Importantly, this phenotype can be pushed to metastatic disease with as little as one other genetic mutation (9) . We have introduced the PB-SMART system into the prostate specific Pten -/-background to increase the chances of identifying mutations that drive progression to metastatic disease. 
To analyze the human prostate cancer tissues for possible abnormal expression and/or mutations of the candidate genes identified in the mouse model.
We are currently mapping transposon insertions from our collection of prostate tumors to identify recurrently affected genes or pathways. We are also increasing the screening cohort to induce a larger collection of prostate tumors. Once we identify recurrently mutated genes or pathways we will examine them in human cancer prostate tissues with our collaborator Dr. Liu. 
KEY RESEARCH ACCOMPLISHMENTS:
• Established the PB-SMART system for cancer gene discovery in the mouse.
• Implemented PB-SMART in the prostate to identify mutations that induce progression and metastasis.
• Identified and implemented strategies to increase the efficiency of the screen to reduce time and cost.
REPORTABLE OUTCOMES:
Manuscripts:
Establishing the PB-SMART system and implementing it for cancer gene discovery has resulted in one published article and one article under review. 
CONCLUSION:
We have established the PB-SMART system and are implementing it for cancer gene discovery in the prostate. We isolated a collection of tumors, which we are using to identify causative mutations driving progression. Once identified, these driver genes and pathways will be analyzed in human prostate tumors to confirm their relevance to the human disease. Furthermore, we have identified strategies to increase the mutagenesis efficiency of PB-SMART in the prostate. Optimizing screening efficiency will increase the penetrance and progression of the prostate tumors, and as a result reduce time and cost. Thus, we are poised to identify mutations that drive prostate tumor progression and metastasis, which should contribute to a better understanding and treatment of advanced stage cancer. 
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Abstract:
Exome sequencing has revealed that somatic mutations in human melanomas greatly exceed those in other cancers, making it a challenge for predicting causative genes from the large collection of mutations. Here we used low-copy piggyBac (PB) transposon mutagenesis in mice with conditionally activated Braf in melanocytes to screen for genes promoting melanoma development. Analysis of eleven PB-induced melanomas revealed on average four mutated genes per tumor, circumventing the problem of high background mutations. The two bona fide melanoma drivers relevant to patients with oncogenic BRAF mutations, CDKN2A and MITF, were identified, demonstrating the validity and efficiency of the screen. Notably, analysis of the identified genes in conjunction with human melanoma mutational data revealed two recurrently mutated networks involving MAGI2 and MAP3K1/2, and disruption of MAGI2 can transform human melanocytes. Overall, 34 out of 38 identified genes are mutated in human melanomas, providing invaluable instructive information for sorting through the large collection of mutations and differentiating genes important for melanomas. In summary, low-copy transposon mutagenesis in mice offers a powerful and complementary way to decipher relevant alterations for human conditions, especially those accompanied by high degrees of genetic variation.
One Sentence Summary: Melanomas induced with low mutation rates by piggyBac transposon mutagenesis help pinpoint genes important for human melanomas.
Main Text:
Cancer is driven by the somatic acquisition of genetic alterations, and identification of mutated genes is critical for understanding the underlying mechanisms that drive cancer and designing therapeutics. With the improvements in sequencing power, sequencing of proteincoding regions has proven to be highly effective in identifying mutations in human cancers. This approach is particularly fruitful in identifying causative mutations for many types of cancers, which harbor on average 60-70 somatic mutations (1-3), and those mutations driving tumorigenesis can be distinguished by their higher-than-background mutation rates. However, it has remained difficult to predict causative mutations for cancers with elevated background mutation rates such as melanomas, which have ten-fold more mutations (4-9). Thus, additional approaches are needed to differentiate those genes important for melanomas from passenger mutations.
Since piggyBac (PB) and Sleeping Beauty (SB) cut-and-paste transposons were demonstrated to mobilize in mice (10, 11) , transposon somatic mutagenesis screens have represented promising avenues for cancer gene discovery in conjunction with human cancer sequencing data (12) (13) (14) . For example, SB insertional mutagenesis screens have been successfully conducted for colon and pancreatic cancer in mice (15) (16) (17) . Moreover, the high efficiency of PB transposition permits screens to be performed using few mutagenic transposons, offering the additional advantage of circumventing high background mutation rates in identifying causative mutations. We have previously developed a highly efficient, lowcopy PB mutagenesis system (PB-SMART) utilizing a seven-copy PB mutator called Luc-PB[mut]7, which can also monitor mutagenesis by luciferase expression (14) . We used this system to conduct a low-copy transposon mutagenesis screen for melanomas in mice and analyzed the mouse mutational data together with human melanoma sequencing data. We performed a forward genetic screen for melanomas by introducing our low-copy PB somatic mutagenesis system into this double transgenic background (Fig. 1A) . (25, 26) . Meanwhile, a convergence of three independent insertions in the coding direction in Arhgef3, which encodes a guanine nucleotide exchange factor for Rho family members, supports a recent finding from melanoma exome sequencing that Rho family GTPases may be novel melanoma oncogenes (9) .
Low-copy PB
With a collection of five mutations altogether, Map3k1 and Map3k2, components of the Mapk pathway, were the most frequently mutated genes found among PB-induced melanomas.
Transposon insertions in Map3k1 were clustered in introns 9 and 10 ( Fig. 3A) . The clustering of insertions in this region is not due to an enrichment of PB target sites (TTAA) and thus suggests a functional significance. Indeed, all these insertions are oriented in the coding direction and cause overexpression of the truncated Map3k1 C-terminal product containing the kinase domain ( Fig. 3B-E) . Similar to Map3k1, insertions in Map3k2 also overexpress the C-terminal kinase domain as described above (Fig. 2D ).
Approximately 65% of human melanomas harbor oncogenic BRAF lesions. It is interesting whether the rest of patients without BRAF mutation also rely on MAPK pathway activation. It is known that MAP3K1/2 members can activate MAPK signaling independent of BRAF (27, 28) , raising the possibility that MAP3K1/2 could substitute for BRAF in melanomas.
The conditional Braf allele in our screen made it possible to examine whether Braf was activated in Map3k1/2-mutated melanomas. We found that Braf V600E and Map3k1/2 mutations were mutually exclusive in all but one PB-induced melanomas ( Fig. 3F and Table 1 ; segregation of these mutations could not be distinguished in one tumor because it contained both Braf activated and non-activated cells). These data support the notion that Map3k1/2 can functionally substitute for oncogenic Braf to activate the Mapk pathway in promoting melanomas (Fig. 3G ).
Analysis of Mouse Mutational Data in Conjunction with Human Melanoma Sequencing
Data. High mutation rates in human melanomas make it difficult to distinguish causal alterations from passengers. Since a small collection of mutations has been identified in our low-copy PB mutagenesis screen for driving melanomas in mice, comparing our results with human melanoma mutational data could not only validate our screen but also provide important instructive information for differentiating melanoma-promoting genes in humans.
Indeed, CDKN2A and MITF, the two highly prevalent, bona fide melanoma drivers relevant to patients with oncogenic BRAF mutations, were identified in our collection. Although only several bona fide melanoma drivers are known, other genes important for melanomas must exist in human exome sequencing data sets (5) (6) (7) (8) (9) . The intersection between the small number genes identified in our melanoma-promoting mutagenesis screen in mice with the mutations found in human exome sequencing data could be an informative approach to differentiate genes that are potentially important for human melanoma development. For example, one of the genes at this intersection was MAGI2. In addition, we interestingly found that MAGI2 is involved in a protein interaction network in which many members are mutated in both our screen and human melanomas or in one of the data sets ( Fig. 4A ) (5) (6) (7) (8) (9) 24) . We found that depletion of MAGI2 (Fig. 4B-C ) conferred anchorage-independent growth to human melanocytes stably expressing BRAF V600E in soft agar assays ( Fig. 4D-E) (25) . Collectively, these results provide proof-of-principle examples indicating that low-copy transposon mutagenesis in mice and intersectional analysis with human melanoma exome sequencing data are highly useful for distinguishing genes important for melanomas.
We compared genes from our screen to mutational data in human melanomas as One possibility is that the high mutation rate in human melanomas obscures the causal mutations ( Fig. 5C ). We thus calculated the expected random mutation frequencies taking into account the size of each gene and the average melanoma mutation rate of 650 mutations per tumor (5-9) and compared those with the detected mutation frequencies revealed by melanoma exome sequencing ( Fig. 5D ; expected x-axis, observed y-axis; orange line represents equal value of observed versus expected). Interestingly, only CDKN2A, a very small gene, is significantly mutated above the expected random mutation frequency (Fig. 5D ). Moreover, even MITF is mutated much less frequently than expected by chance despite having been independently verified as a bona fide melanoma driver ( Fig. 5D ) (25) . However, if the mutation rate were ten times lower, as found in other cancer types (1-3), most of these genes including MITF would have detected mutation frequencies higher than expected ( Fig. 5D ; green line). This illustrates why exome sequencing is a highly effective approach for identifying causal mutations in many cancers (1-3) and underscores how high mutation rates could complicate this approach.
Indeed, after more than 150 melanomas sequenced, few predicted candidate drivers have been corroborated by independent sequencing studies (5-9). The low-copy transposon mutagenesis in mice in conjunction with the human exome sequencing data is thus particularly useful to differentiate human somatic mutations and identified a group of genes important for melanomas. This approach represents a powerful way for identifying genes relevant to diseases, especially those that are affected by high mutation rates. 
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Materials and Methods
Figure S1
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References ( genotyped by coat color and fluorescent eye marker, respectively (11, 13) . Braf CA and Tyr-CreER mice were genotyped as described previously (20, 22) . To activate CreER, newly weaned mice were administered 1 mg tamoxifen mixture in sunflower seed oil for five consecutive days by intraperitoneal injection. For luciferase imaging, mice were sedated by isoflurane and injected with luciferin as described previously (13) . To assess Braf allele recombination by PCR, Braf
V600E
(334 bp) and Braf CA (307 bp) products were resolved by 15% native PAGE.
Histology and immunohistochemistry. Melanomas were fixed in 10% neutral-buffered formalin overnight, dehydrated via increasing concentrations of ethanol and xylenes, paraffinembedded and sectioned. Sections were stained with hematoxylin and eosin. For immunohistochemistry, heat-induced antigen retrieval in sodium citrate was performed on unstained sections after rehydration. MAP3K1 (rabbit anti-MEKK1, Millipore #07-1476) and S100 (rabbit anti-S100 Ab-2, Thermo Scientific #RB-044-A1) antibodies were used. Slides were developed using a diaminobenzidine-peroxidase substrate kit (Vector Labs) and counterstained with hematoxylin.
Mapping transposon insertion sites. For initial examination of the nature of PB insertional mutations, we cloned and sequenced PCR-amplified melanoma insertion products by Sanger sequencing using a linker-mediated PCR protocol described previously (13) . Results were mapped against the mouse genome using the BLAT tool on the UCSC Genome Browser (http://genome.ucsc.edu) (31) . For Illumina high-throughput sequencing and mapping, indexed primers containing unique 8-bp tumor identifier sequences were used for the secondary PCR.
Sequencing primers were designed to the outermost transposon ends (table S3) (table S3) .
RT-PCR.
Melanomas were macrodissected and snap frozen in liquid nitrogen. Frozen tissue was homogenized using a bead mill homogenizer (Qiagen). Cell lysates were homogenized by passing through a 20-gauge syringe. Purified RNA was used with a blend of oligo(dT), random primers and iScript reverse transcriptase (Biorad) to synthesize cDNA.
Quantitative RT-PCR with SYBR green in the StepOne Real-Time PCR Instrument (Applied Biosystems) was performed in triplicate for each sample to determine mRNA levels using the relative standard curve method ( Statistical Analysis. The expected random mutational frequencies for genes being mutated by chance were calculated factoring in the size of the coding sequence for each gene and the average human melanoma mutation rate of 650 mutations per tumor (5-9). All calculations were performed under the assumptions that the probability of mutation at all possible positions of the exome is equal, each gene is mutated once per tumor and mutational events are independent. χ 2 tests were used to assess the statistical significance of observed versus expected mutational frequencies. The Yates correction was applied as necessary.
Analysis of protein interaction networks.
We utilized the Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) to build networks of experimentally validated, functional human protein associations (30) . A confidence score of 0.6 or higher was used. Transposon insertions in all 15 randomly chosen insertional mutations were detected by PCR. Table S1 . Insertional mutations in 11 PB-induced melanomas. 
Melanoma Gene Orientation relative to transcription Insertion site in transcription unit
human PTPRO For knockdown of MAGI2 and PTPRO by shRNA 
Abstract
Somatic forward genetic screens have the power to interrogate thousands of genes in a single animal. Retroviral and transposon mutagenesis systems in mice have been designed and deployed in somatic tissues for surveying hematopoietic and solid tumor formation. In the context of cancer, the ability to visually mark mutant cells would present tremendous advantages for identifying tumor formation, monitoring tumor growth over time, and tracking tumor infiltrations and metastases into wild-type tissues. Furthermore, locating mutant clones is a prerequisite for screening and analyzing most other somatic phenotypes. For this purpose, we developed a system using the piggyBac (PB) transposon for somatic mutagenesis with an activated reporter and tracker, called PB-SMART. The PB-SMART mouse genetic screening system can simultaneously induce somatic mutations and mark mutated cells using bioluminescence or fluorescence. The marking of mutant cells enable analyses that are not possible with current somatic mutagenesis systems, such as tracking cell proliferation and tumor growth, detecting tumor cell infiltrations, and reporting tissue mutagenesis levels by a simple ex vivo visual readout. We demonstrate that PB-SMART is highly mutagenic, capable of tumor induction with low copy transposons, which facilitates the mapping and identification of causative insertions. We further integrated a conditional transposase with the PB-SMART system, permitting tissue-specific mutagenesis with a single cross to any available Cre line. Targeting the germline, the system could also be used to conduct F1 screens. With these features, PB-SMART provides an integrated platform for individual investigators to harness the power of somatic mutagenesis and phenotypic screens to decipher the genetic basis of mammalian biology and disease.
Introduction
Transposon insertional mutagenesis (TIM) is a powerful tool for inducing and identifying mutations of interest and has been utilized with great effect in many organisms, from the bacterium to the fruit fly Drosophila melanogaster [1, 2] . The Sleeping Beauty (SB) and piggyBac (PB) DNA transposons have been recently developed for TIM in mice and human cells [3, 4, 5] . As one of the first applications of TIM in mammals, SB and PB have been used to identify tumor-promoting genes for multiple tumor types in mice [6] [7] [8] [9] [10] [11] [12] [13] . In addition, SB transposase has been activated by tissue-specific Cre expression for the successful induction of colorectal adenocarcinoma, hepatocellular carcinoma, and B-cell lymphoma [10, 11, 13] . The successful induction of tumors by SB and PB indicates that a more versatile somatic TIM system can be established for broad application.
Somatic genetic screening requires animal breeding and significant lengths of time for manifestation of phenotypes such as tumorigenesis. Thus, it represents substantial investments of cost and time for mammals. Although tumor induction by SB TIM has been successful in multiple tissues, tumors in a number of other tissues have yet to be found despite employing the same mutator transposons and whole-body mutagenesis approach. This highlights the importance of determining the feasibility of TIM for the tissue of interest. Although one could molecularly determine mutagenesis efficiency before the manifestation of phenotype, it is not desirable to sacrifice valuable experimental animals during the course of the screen. It would be ideal to have a method to easily determine whether TIM in a targeted tissue is feasible at the outset of the screen without sacrificing animals.
Moreover, while tumors are readily identifiable, pre-tumorous lesions and metastatic clones are difficult to locate without visible markers. Furthermore, marking mutant clones is a prerequisite for screening and analyzing most other somatic phenotypes. Visibly marking mutant somatic clones has been employed in Drosophila, zebrafish, and mice and demonstrated to have tremendous utility in analyzing a variety of processes including cell proliferation and migration, neurobiology and other clonal behaviors in vivo [14] [15] [16] [17] . Thus, a somatic TIM system that can be used to screen for phenotypes other than tumor formation must incorporate the ability to track mutagenized cells.
Somatic mutagenesis screening has the genetic power to conduct genome-wide interrogation with a small number of animals. A highly efficient somatic TIM system would allow genetic screens to be performed with low copy numbers of transposon, thus allowing easy identification of causative mutations. Finally, it is optimal that the genetic elements for the features described above to be integrated such that somatic TIM can be conducted with one generation of breeding.
The PB transposon system has been shown to be highly efficient in mammals [3] . Its distinct properties of precise excision [3, 18] , large payload capacity [3] , and genome-wide insertion tendency [3, 12] offer a unique opportunity to create a somatic TIM system with broad utility. Here, we describe a method for PB somatic mutagenesis with an activated reporter and tracker in mice (PB-SMART). In this system, mobilization of the PB mutator transposon activates luciferase for the ex vivo reporting of mutagenesis activity levels, providing feasibility assessment at the outset of a genetic screen. The activation of luciferase or a red fluorescent protein also featured in this system further enables visual tracking of mutated cells. The integration of the mutagenesis reporter, mutant cell tracker, and mutagenic transposon into a single transgene greatly simplifies genetic breeding. Further incorporation of Cre-inducible PB transposase (PBase) transgenes allows tissue-specific somatic TIM screens to be conducted with one genetic cross. Finally, we show that PB-SMART can induce somatic phenotypes, track clonal behavior of mutated cells, and allow easy identification of causative insertions. Thus, PB-SMART provides a powerful means for individual investigators to decipher the genetic basis of mammalian biology and disease.
Results
Generating a PB mutator transposon for multiple genomic contexts
PB has previously been found to integrate at high frequency near or within genes [3] . To efficiently induce somatic mutations, we generated a PB mutator transposon ( Figure 1A , PB[mut]) to induce ectopic gene expression in multiple genomic contexts. The CMV early enhancer/chicken b-actin promoter was cloned between the PB transposon arms to induce overexpression of genes downstream of a transposon insertion site. A myc epitope in all three reading frames and a splice donor were placed after the Actin promoter such that transcription and translation initiation can incorporate the myc tag sequence prior to splicing into endogenous exons. The CMV enhancer can also act as a bidirectional enhancer to upregulate genes. Additionally, in the event that PB[mut] inserts into an intron, an N-terminally truncated product can be ectopically induced. Insertions into introns can also produce C-terminally truncated gene products initiated by the endogenous promoter. A splice acceptor followed by a sequence with stop codons in all three frames and a poly(A) signal was added for this purpose. Expression of truncated genes may produce dominant active and dominant negative proteins. Thus, by design, the PB[mut] transposon can induce the ectopic expression of full-length or truncated endogenous genes in many different genomic contexts ( Figure 1A) . Indeed, PB[mut] can induce ectopic full-length and truncated gene expression in PB-SMART screens (see below).
PB somatic mutagenesis with an activated luciferase reporter
In order to develop a somatic mutagenesis system that can induce mutations while simultaneously and non-invasively (ex vivo) reporting mutagenesis levels in tissues, we engineered a strategy to bioluminescently mark cells in which transposon mobilization has occurred. We took advantage of the highly sensitive luciferase reporter gene [19] by inserting PB[mut] at a TTAA tetranucleotide target site within the coding sequence ( Figure 1A , Luc-PB[mut]), thereby preventing luciferase expression from an upstream Actin promoter. During mutagenesis, active PB transposase (PBase) catalyzes the precise excision of the PB mutator transposon and a full-length luciferase product is reconstituted ( Figure 1A) . Five Luc-PB[mut] transgenic lines were established and their ability to report PBase activity was tested by crossing to our previously described Act-PBase line [3] . The Luc-PB[mut]7 line was identified as the most robust reporter for PB mutagenesis activity that can be easily assayed by ex vivo imaging ( Figure 1B) . Luc-PB[mut]7 behaves as a faithful reporter for PBase activity, since it does not produce any luciferase signal in mice lacking PBase ( Figure 1B) .
To examine whether Luc-PB[mut]7 can differentiate between varying levels of PBase activity, we generated transgenic mice expressing a PBase-Estrogen Receptor fusion transgene (ActPBaseER). In the inactive state, the PBaseER protein is sequestered in the cytoplasm. Stimulation with tamoxifen shuttles PBaseER to the nucleus and activates its ability to drive PB transposition ( Figure S1 ). In vivo, luciferase signal was not observed in newly weaned, untreated Luc-PB[mut]7;Act-PBaseER transgenic mice. However, transgenic Act-PBaseER can mobilize PB upon tamoxifen administration ( Figure 1C ) and luciferase signal can be detected one week after treatment, providing a tool for conditional PB TIM. Quantitative PCR measuring PB[mut] excision revealed that PBaseER activity levels were significantly lower than those of Act-PBase ( Figure 1C) . These results were corroborated by the luciferase mutagenesis reporter signal from ex vivo imaging ( Figure 1C) . Furthermore, we sometimes observed leaky luciferase signal in older, untreated mice housed together with tamoxifentreated mice (data not shown). This signal, however, is at least an order of magnitude lower than signal from treated mice as measured by ex vivo imaging (data not shown). The ability to differentiate between differing levels of luciferase signal indicates that Luc-PB[mut]7 is a sensitive reporter for PBase activity.
By real-time PCR analysis, the Luc-PB[mut]7 transgenic line was found to contain seven copies of the mutagenic transposon. When crossed to Act-PBase mice, the number of live-born double transgenic pups was 93% of the expected number (n.100). Since mutagenesis in Luc-PB[mut]7;Act-PBase mice was observed in all tissues as reported by luciferase, we addressed whether this low copy line is sufficient to induce different phenotypes when mutagenesis is targeted in all tissues or specific organs. We found Luc-PB[mut]7 can induce tumor formation as well as other phenotypes including cellular features (e.g., cell infiltration and clonal expansion) and morphological defects (e.g., alopecia) (also see below).
We found that body-wide PB-SMART can induce tumor formation in non-sensitized backgrounds. We observed that Luc-PB[mut]7;Act-PBase and Luc-PB[mut]7;Act-PBase;Cre mice developed tumors while conducting sensitized screens. Nine out of 32 of these Luc-PB[mut]7;Act-PBase(Cre) mice developed tumors within 50 weeks while only one out of seventeen Act-PBase(Cre) and zero out of 32 Luc-PB[mut](Cre) controls developed a tumor ( Figure 1D ). We have collected additional tumors from cohorts that have not reached 50 weeks and other non-sensitized cohorts containing floxed latent alleles of Pten loss or Braf activation [20, 21] . Across these cohorts, we have observed similar tumor types including kidney and pancreatic tumors, lung adenocarcinoma, hepatocellular carcinomas, soft tissue sarcomas such as angiosarcoma and small round blue cell (SRBC) tumors, and skin tumors such as squamous cell carcinoma, sebaceous cancer, and melanoma. These results confirm that our low copy PB-SMART system can efficiently induce tumor-promoting mutations in a wide variety of tissues.
We also found that the low copy mutagenic transposon in the PB-SMART system allows for easy identification of potential causative insertional mutations. Transposon insertions from tumors were mapped by linker-mediated PCR (LM-PCR). On average, across 45 tumors analyzed, 6.1 PB insertions were mapped. Notably, greater than 64% of all insertions were recovered in introns, exons, or within ten kilobase pairs (kb) of either known or predicted genes (Table 1) . Given the propensity of Luc-PB[mut] for inserting into or near genes in these tumors, we analyzed whether the mutator transposon was oriented along or opposite the coding direction of inserted genes. Because our mutator transposon is designed to overexpress full-length genes or truncated genes, we expected that in tumors, insertions oriented along the coding direction of nearby or affected genes would be enriched versus insertional orientation by random chance. Indeed, over 64% of intron insertions were oriented along the coding direction of the affected genes, and almost 60% of insertions within 10 kb upstream of genes were oriented toward the coding direction of the nearby genes (Table 2) . Meanwhile, insertions within 10 kb downstream of nearby genes displayed less bias for mutator orientation (Table 2 ). These data imply that the PB mutator transposon is indeed upregulating genes important for tumorigenesis.
In five kidney tumors, we identified common insertions in Mitf. The mutator transposons in all five tumors were inserted in the coding direction, upstream of the translational start of the Misoform, suggesting overexpression of Mitf in these tumors (Figure 2A) . Indeed, quantitative PCR revealed that Mitf was upregulated in these kidney tumors as compared to two wild-type kidney samples ( Figure 2B ). Histopathology of the kidney tumors revealed an expansion of nests of pleomorphic spindle and epithelioid cells suggestive of carcinoma ( Figure 2C) .
Notably, two other members of the MiT family of basic-helixloop-helix/leucine zipper transcription factors, TFE3 and TFEB, have been recurrently affected by translocations that result in the upregulation of these transcription factors in human pediatric renal cell carcinoma [22] [23] [24] [25] [26] . Since TFE3, TFEB, and MITF are highly homologous and bind to the same DNA consensus sequence, it is likely that they can substitute for each other as oncogenes [27] . Together, these data suggest that MITF upregulation is an important driver for kidney tumor formation.
We also identified Gli2, a downstream effector of the Hedgehog (Hh) signaling pathway [28] , as a common insertion site in SRBC tumors. We mapped coding-direction insertions in intron 7 or intron 8 from 11 tumors displaying SRBC morphology ( Figures 2D  and 2E ). Gli2 contains a repressor domain in the amino-terminus, and expression of the C-terminal portion of Gli2 has previously been shown to result in the constitutive transcriptional activation of downstream target genes [29, 30] . In these sarcomas, it is likely that the Gli2 insertions lead to the expression of constitutive transcriptional activator forms of Gli2 that drive tumor formation. In fact, constitutive Hedgehog signaling in Gorlin's syndrome due to mutation in PTCH leads to an increased propensity to develop an SRBC tumor, rhabdomyosarcoma [31, 32] . Furthermore, activation of Gli1 (a Gli2 transcriptional target) seems to be a major downstream effector of the EWS-FLI1 oncoprotein which drives another SRBC tumor, Ewing Sarcoma [33, 34] . Together these data strongly support the notion that constitutive Hedgehog signaling is a critical driver in SRBC tumor formation, with overexpression of truncated Gli2 being one mechanism. Thus, the identification of cancer genes with known human relevance validates the utility of our low-copy mutator for uncovering disease genes.
PB somatic mutagenesis with an activated RFP cell tracker
In somatic mutagenesis, the ability to track mutated cells via the same transgenic line used to induce mutations opens up many experimental possibilities. We thus added new elements in our PB mutator transposon to label the mutant cells. The RFP coding sequence and an internal ribosome entry site (IRES) were inserted between the Actin promoter and myc-SD, which contains start codons in all three reading frames followed by a splice donor, of PB[mut] ( Figure 3A , PB[mut-RFP]). Following insertions into introns or 59 regulatory regions, production of bicistronic pre-mRNA containing RFP, IRES, the engineered myc-SD exon, and downstream endogenous intron and exon sequences can be initiated by the Actin promoter. After splicing of the myc-SD exon to downstream endogenous splice acceptors, the bicistronic transcripts enables the expression of RFP and the ectopic expression of endogenous proteins ( Figure 3A) . When we tested this mutator in cultured cells, the activated RFP marker was co-expressed in cells that ectopically expressed downstream endogenous proteins that incorporated the engineered myc-SD exon ( Figure 3B ). In order to ensure that PB[mut-RFP] does not express RFP from a transgenic concatamer, a concatamer silencer (CS) was inserted outside of the transposon ( Figure 3A) . The CS contains a splice acceptor followed by stop codons in all three reading frames to terminate transcripts initiated by the Actin promoter from transgene concatamers. To prevent alternative splicing-mediated exclusion of the CS splice acceptor, a sequence forming a pre-tRNA-like (DAC) structure was cloned after the stop codons. This substrate is efficiently recognized and cleaved by RNase P ensuring that pre-mRNA which contain the CS do not form mature transcripts [35] .
We generated seven transgenic lines varying in transposon copy number from two copies to 200 copies ( Figure 3C ) and found that none were RFP-positive, indicating that the CS successfully prevents undesired RFP production. When the two highest copy lines were crossed to the Act-PBase line, live-born double transgenic progeny were rarely observed ( Figure 3D ), suggesting that the mutagenic transposons can be mobilized by Act-PBase during embryonic development and can induce significant deleterious effects and embryonic lethality. The mobilization of the low copy PB[mut-RFP] lines was also confirmed by excision PCR ( Figure 3E ). Importantly, mutagenesis using either of the two-copy or the seven-copy PB[mut-RFP] lines crossed to Act-PBase mice resulted in the appearance of RFP-positive patches ( Figure 3F ) and triggered tumorigenesis ( Figure 3G ), validating these three low copy PB[mut-RFP] lines for somatic mutagenesis with an activated cell tracker.
Tissue-specific PB somatic mutagenesis screening with an activated reporter and tracker (PB-SMART screen)
We have shown that the collective luciferase signal in tissues generated by Luc-PB[mut]7 can act as a robust reporter of mutagenesis activity. Since Luc-PB[mut]7 is also a mutator, the luciferase signal could also be used to mark the mutant cells. Given that Luc-PB[mut]7 is a low copy line and not every cell in a tissue will be luciferase positive, we reasoned that clones or patches of mutant cells will have elevated signals and could be detected through ex vivo imaging. In this sense, the luciferase reporter also behaves as a tracker for mutant cells. By monitoring ex vivo luciferase signal, we identified clonal patches in the skin and tracked the appearance of melanomas in Luc-PB[mut]7;ActPBase;Braf CA ;Tyr-CreER mice (Figures 4A and 6A ; also see below). In addition, the luciferase signal enabled the identification of tumor cell infiltration into distant organs of a Luc-PB[mut]7;ActPBase;Pten +/-mouse that developed lymphoma ( Figure 4B ). The enlarged thymus and lymph nodes were strongly luciferase-positive due to the dense clustering of cells that activated the luciferase reporter ( Figure 4B ). Strong signal was also seen emanating from a distinct portion of the liver ( Figure 4B ). Histology revealed that the luminescent spot was indeed infiltration of lymphocytes ( Figure 4C ), and we mapped identical transposon insertions from the liver infiltration and other tumor sites, indicating that the cells originated from the same clone. Thus, the Luc-PB[mut]7 line is a mutant clone tracker for monitoring clonal expansion, tumor formation, and infiltrations of cells into foreign tissues.
We further expanded the PB-SMART system for tissue-specific genetic screens. To allow the system to be readily adopted for screens in many types of tissues and cells, we generated transgenic mice in which PBase or PBaseER can be activated by tissue-specific Cre by inserting a Stop-pA sequence flanked by loxP sites between the Actin promoter and the transposase coding sequence ( Figure 5A , LSL-PBase, LSL-PBaseER). When these double transgenics were crossed into lines expressing Cre in the kidney and genitourinary tract or the skin epithelium [36, 37] , correct targeting of mutagenesis to these tissues was confirmed by the luciferase reporter ( Figures 5B and 5C ).
To ask whether Luc-PB[mut]7 can be used to track mutationdriven expansion of cells, we utilized the Tyr-CreER line, which expresses CreER specifically in melanocytes [38] , one of the least densely clustered cell types in the body. Tyr-CreER has been used to conditionally activate Braf V600E , thereby promoting melanocyte proliferation [20, 21] . We generated Luc-PB[mut]7;LSL-PBase; Braf CA ;Tyr-CreER quadruple transgenic mice and assayed whether luciferase can track mutation-driven expansion of cells ex vivo. After administering tamoxifen, we were able to detect luciferase signal in melanocytes in the ears, tail, and dorsal trunk and also track the expansion of the positive cells over time ( Figure 5D ).
To further illustrate that Luc-PB[mut]7 can be used to track clonal expansion in specific cell types, we targeted the PB-SMART system to the mouse skin. We generated Luc-PB[mut]7;LSLPBase;K14-Cre mice which express Cre specifically in the basal keratinocytes of the epidermis. This compartment contains the stem and progenitor cells that give rise to the hair follicle, sebaceous gland, and interfollicular epidermis [39] . We reasoned that if a keratinocyte stem or progenitor cell were to be targeted by PB-SMART, over time an entire clonal unit would become luciferase positive. Indeed, the appearance of distinct luciferase clusters could be detected in these mice ( Figure 6A ).
Skin-specific PB-SMART resulted in tumor development as well as other morphological phenotypes. For example, we observed hair loss on dorsal skin, resulting from PB mutagenesis and marked by luciferase signal ( Figure 6B ). Keratin staining of frozen sections revealed a striking epidermal thickening in the affected region (Figures 6C and 6D ). We mapped a transposon insertion upstream of Myc in the affected skin ( Figure 6E ). This is consistent with previous reports that in K14-c-Myc transgenic mice, epidermal stem cell proliferation and differentiation results in hair loss, hyperproliferation, and thickening of the interfollicular epidermis [40, 41] .
We further analyzed skin tumors that were induced and labeled by skin-specific PB-SMART. We were able to observe tumors in Luc-PB[mut]7;LSL-PBase;K14-Cre mice starting at four months of age. Using the ex vivo reporter system, we can detect regions of luciferase activity prior to tumor formation, that correspond to the later development of tumors ( Figure 6F ). In four of these tumors, we identified transposon insertions in Gli2 ( Figure 6G ). Quantitative PCR confirmed that Gli2 mRNA levels were increased in these tumors as compared to wild type skin ( Figure 6H ). Constitutive activation of the Hh pathway is characteristically seen in basal cell carcinoma (BCC) [42] , which arises from stem cells in the epidermis and hair follicle [43, 44] . Furthermore, histopathology of the skin tumors revealed palisading basaloid cells forming tumor nests and retraction of the stroma from the tumor islands in formalin-fixed sections similar to human BCC ( Figure 6I ). Together, these data show that the PB-SMART system can be deployed to conduct tissue-specific genetic screens and identify causative mutations relevant to human disease.
Discussion
In the data presented, we have taken advantage of the PB transposon's properties to create a somatic mutagenesis system, PB-SMART, to simultaneously mutate and mark cells for conducting tissue-specific genetic screens in mice. In somatic screens for cancer genes, PB-SMART offers advantages over other TIM systems. Our system allows one to detect tumors before their morphological manifestation and to monitor tumor growth and dissemination ex vivo. Importantly, it allows one to detect tumor formation ex vivo such that only tumor-positive animals will be sacrificed in a screen. This is particularly critical for screens of internal cancers as previous screens required sacrificing large numbers of experimental animals at arbitrary time points to search for tumors. The visible cell markers also enable mutant clones in tissues to be readily identified and continuously monitored over time. This is essential for the detection of phenotypes other than tumors and provides many experimental advantages for visualizing proliferation defects, tracking cell migration, tracing cell lineages, and analyzing other clonal behavior in vivo. As proof-of-principle examples, we demonstrated that the system can be used to identify phenotypes in PB mutant clones, detect cell infiltration, and track the expansion of rare cell populations. In addition to these examples, the luciferase and RFP mutator lines can be utilized in other ways to confer specific experimental advantages according to the biological process to be surveyed. For example, luciferase is highly useful for detection and tracking of solid tumors originating from deep tissues. On the other hand, RFP enables detection and isolation of cells via fluorescence-activated cell sorting which would be particularly useful for capturing disseminated tumor cells in the bloodstream. As an additional resource to facilitate use by the research community, we will provide further detailed characterization of these and other recently developed PB-SMART lines on our lab website (http:// info.med.yale.edu/genetics/xu).
The luciferase reporter integrated into the PB-SMART system also allows mutagenesis efficiency to be visually assessed at the onset of a genetic screen without sacrificing animals. Furthermore, we have found that luciferase signal activated by PB mutagenesis is highly indicative for the successful outcome of a mutagenesis screen, providing a valuable predictive tool. Genetic screens in mice are a significant investment. Since phenotypes in many screens take significant time to manifest, it is a tremendous advantage to have a predictive indicator at the beginning of the experiments.
PB-SMART is also a highly efficient mutagenesis system. Utilizing PB's large payload capacity, we engineered elements in PB to ectopically express genes or parts of genes and to terminate transcripts upon insertion in many genomic contexts, thereby creating highly mutagenic transposons. Together with PB's high transposition efficiency and genome-wide distribution, PB-SMART is able to induce somatic phenotypes with low copy (seven or fewer) transposons. The efficiency of the system is highlighted by the fact that a broad spectrum of tumors is induced with only seven copies of transposon. Importantly, low transposon copy numbers allow for more straightforward identification of causative insertions because there are fewer bystander insertions. We found that over 64% of insertions in tumors are mapped in introns, exons, or within 10 kb of genes. This is a remarkably high gene insertional frequency indicative that there is a selective advantage for PB gene insertions in tumors. In two tumor types that have not previously been found in somatic mutagenesis screens, we used common insertion site analysis to identify Mitf as a driver in kidney tumor formation and truncated Gli2 as a driver of SRBC tumors. Thus, PB-SMART is a powerful tool to identify mutations relevant to human disease.
For the creation of a tissue-specific mutagenesis system that can be readily used by the research community for a variety of tissue and cell types, we generated conditional transposase transgenic lines that can be activated by Cre (LSL-PBase and LSL-PBaseER). We showed that mutagenesis can be targeted specifically to the skin or internal organs by crossing to tissue-specific Cre lines. Temporal control of tissue-specific mutagenesis can also be achieved by using LSL-PBaseER or by crossing to available CreER lines, as we demonstrated in melanocytes with Tyr-CreER. Given that specific Cre or CreER lines have been generated for almost every mouse tissue being studied, our system will make it possible to target any tissue for genetic screens. The combination of conditional transposase lines and low copy PB mutator lines could be used to target the germline for the generation of stable and heritable mutations for traditional screens. More importantly, mutations targeted at the germline could also be used to conduct F1 screens for developmental and physiological phenotypes including embryonic and adult defects.
In summary, the ability to induce somatic mutations, report mutagenesis levels, and track mutated cells permits many types of applications and analyses that are not possible with current TIM systems. Because induction and labeling of mutant cells are simultaneously achieved by the same mutator transposon, the design not only links the two events, but also simplifies genetics by minimizing the number of transgenes involved. Furthermore, PB-SMART also integrates the conditional transposase, which enables TIM screens to be conducted for any tissue in the mouse by a single genetic cross to a tissue-specific Cre line. The ability to screen thousands of clones in a single animal in only one generation makes it possible to achieve genome-wide interrogation with a small number of animals in a short period of time. The development of PB-SMART thus empowers individual investigators to decipher the genetic basis of biology and disease by forward genetic screens. 
Methods
Ethics Statement
Plasmid construction
The Luc-PB[mut]7 and PB[mut-RFP] transposons were generated from elements in the plasmids PB[Act-RFP] [3] , pIRES (Clontech), pBS302 (Life Technologies), pDAC [35] , and pGL3 (Promega). Myc-SD was PCR amplified from an oligonucleotide containing ATG transcriptional initiation codons, myc epitope sequences in all three reading frames, and a splice donor sequence. CS and part of SA-stop-pA were PCR amplified from an oligonucleotide containing a splice acceptor and stop codons in all three reading frames (sequences available upon request). For PB[mut-RFP], loxP sites were included to flank the mutagenic Act-RFP-IRES-myc-SD cassette. All elements were constructed on a pBlueScript II SK+ (Stratagene) backbone before cloning between PBL and PBR transposon arms to yield the final plasmid. For Luc-PB[mut], luciferase from pGL3 was introduced outside PBL and PBR by overlapping PCR followed by cloning into the XhoI and NotI sites in PB[Act-RFP].
LSL-PBase plasmid was generated from DNA elements in the plasmids Act-PBase [3] and pBS302. A 1.5-kb transcriptional termination sequence flanked by loxP sites was obtained from the pBS302 plasmid by digestion with EcoRI and SpeI, and subsequently cloned between the Actin promoter and PBase coding sequence in the Act-PBase plasmid. Two copies of the chicken b-globin HS4 core enhancer from the plasmid pNI-CD were also cloned upstream of the Actin promoter.
PBaseER was generated by inserting a 12-nucleotide linker sequence that encodes a four-amino acid, positively charged linker (59-AGGCGCGCCCCC-39) between the PBase coding sequence and the mutated tamoxifen-responsive mouse estrogen receptor hormone-binding domain coding sequence [45] . PBaseER was subsequently cloned after the Actin or LSL promoter. Table S1 for primer sequences).
Mouse lines, breeding and husbandry
Act-PBase, Tyr-CreER, Braf CA , Pten lox/+ , Ksp1.3-Cre (Tg(Cdh16-cre)91Igr/J), and K14-Cre (Tg(KRT14-cre)1Amc/J) lines have been reported previously [3, 20, 36, 37] . Pten +/ were generated by mating a Pten lox/+ male to a Pbsn-Cre4 (B6.Cg-Tg(Pbsn-cre)4Prb) female to induce recombination in the germline [46] . Transgenic mice were backcrossed to the FVB/NJ mouse strain. Animals were fed a standard rodent diet.
Administration of tamoxifen to mice
100 mg/ml tamoxifen was dissolved in ethanol and diluted 1:10 in sunflower seed oil (for intraperitoneal injection) or 1:100 in water (for tamoxifen-water bottles). Newly weaned mice were injected with 100 ml (1 mg) tamoxifen-in-oil mixture once per day for five consecutive days. For tamoxifen-water bottles, mice were constantly kept on 100 mg/ml tamoxifen-water.
Histology and immunofluorescence
For paraffin-embedded sections, tissues were dissected from euthanized mice and fixed in 10% neutral-buffered formalin overnight, dehydrated in a series of increasing concentrations of ethanol and xylenes, embedded in paraffin, sectioned, and stained with hematoxylin and eosin. For frozen sections, dissected tissues were OCT-embedded, frozen, sectioned, and fixed in 4% paraformaldehyde (PFA). For immunofluorescence staining of cytokeratin, OCT sections were fixed for 10 min in 4% PFA in PBS and washed three times for 5 min in PBS. Sections were permeabilized with 0.1% Triton for 15 min, washed three times for 5 min in PBS, and blocked for one hour with blocking solution (5% NGS, 1% BSA, and 0.1% Triton X-100 in PBS). Rabbit anticow cytokeratin wide spectrum screening antibody (1:250, Dako) was added overnight at 4uC. Alexa Fluor 488 goat anti-rabbit IgG (1:2000; Invitrogen) was used for detection of primary antibodies and nuclei were stained with DAPI. Blocking solution and antibody incubation steps were performed in a humidified chamber.
Ex vivo mouse imaging
Mice were sedated using an isoflurane vaporizer. For ex vivo visualization of RFP, sedated PB[mut-RFP] control and PB[mut-RFP];Act-PBase mice were shaved and immediately imaged sideby-side in the IVIS Spectrum (Xenogen) by epifluorescence. Autofluorescence in shaved regions was quantitated in control mice to adjust epifluorescence imaging parameters. To visualize in vivo luciferase activity using the IVIS Spectrum, sedated mice were weighed, treated with 150 mg luciferin per kg body weight via intraperitoneal injection, and subsequently imaged 15 minutes after luciferin injection.. Heart rate and respiration were closely monitored and body temperature was regulated throughout the entire procedure.
Linker-mediated PCR identification of PB insertion sites
LM-PCR mapping of PB mutator insertion sites was performed using a previously developed protocol [47] with the following modifications. Two mg of mouse genomic DNA were digested overnight with Sau3AI or MspI and subsequently heat inactivated. Double-stranded Sau3AI-specific or MspI-specific linkers were ligated to digested genomic DNA in an overnight reaction at 18uC. Ligation products were digested in a second reaction by MfeI to eliminate adaptor-ligated DNA fragments containing mutator transposon at its original site of insertion. Following heat inactivation of enzyme and purification of digestion products (Qiagen), a primary PCR reaction, followed by a nested PCR reaction, were performed. Amplification products were purified (Qiagen), TA-cloned into the pGEM-TEasy vector (Promega), and transformed in competent cells. Colonies were screened for inserts by colony PCR using the T7 and SP6 primers and those containing inserts sequenced by traditional Sanger sequencing. Oligonucleotides used in this procedure can be found in Table S1 .
Sequence analysis and annotation
Insertion sites were mapped by Blatting against the mouse genome with UCSC Genome Bioinformatics Site (http://genome. ucsc.edu/).
RNA isolation and quantitative PCR
RNA was isolated from tumors or wild type tissues (Qiagen). 1-2 mg of RNA was then used with oligo-dT primer and Superscript III (Invitrogen) to synthesize cDNA. Quantitative PCR with SYBR green in the StepOne Real-Time PCR instrument (Applied Biosystems) was used to determine transcript levels with the relative standard curve method. Primers are detailed in Table S1 .
Excision PCR
Quantitative PCR was used to determine the relative excision levels of Luc-PB[mut] from spleen genomic DNA. Mobilization of PB[mut-RFP] from the concatamer was determined by traditional PCR using primers designed against the plasmid sequences flanking the PB[mut-RFP] transposon. Primer sequences are detailed in Table S1 .
Cell culture
HEK 293 cells were grown in DMEM containing 10% FBS under standard conditions. Cells were transfected with circular plasmids using Lipofectamine 2000 according to the manufacturer's instructions (Invitrogen). To select neomycin-resistant colonies, Geneticin (G418) was added to the culture medium at a concentration of 500 mg/ml. For two weeks, culture medium was replaced every 3-4 days and G418 was resupplemented each time. To induce PBaseER activity, 4-hydroxtamoxifen (4-OHT) was added to culture medium to obtain the desired final concentration.
Confocal microscopy
HEK293 cells were seeded onto sterilized cover slips, cultured until 90% confluent, and then fixed in 4% paraformaldehyde (PFA) for 15 minutes at room temperature. Following permeabilization using 0.1% Triton X-100 in PBS (PBST), cells were blocked with 5% normal goat serum at room temperature for 30 minutes and then incubated with primary antibodies. The ERa primary antibody (sc-542, Santa Cruz Biotechnology) and mouse monoclonal anti-myc 9E10 primary antibodies were used. FITCconjugated secondary antibodies were used to visualize proteins. Samples were mounted in Vectashield containing DAPI (Vector Laboratories). Immunofluorescence images were collected using a Zeiss LSM Meta confocal microscope and processed using Adobe Photoshop.
Methylene blue staining
To stain colonies in tissue culture dishes, culture medium was aspirated by vacuum and washed once in PBS. Subsequently, cells were fixed in ice cold methanol for 20 minutes at room temperature. Staining was performed using 0.2% methylene blue solution for one hour at room temperature. Following this step, the culture dishes were rinsed with distilled water to remove residual stains.
Western blotting
Cells were lysed in lysis buffer and protein concentrations of lysates were determined by the BCA Assay (Pierce). Approximately 15 mg of total protein was loaded on a 10% SDS-PAGE gel. Protein was transferred onto the Trans-Blot Transfer Medium (Biorad). Nitrocellulose membranes were blocked at room temperature for 1 hour with 5% milk in PBS, then washed 3 times for 10 minutes in PBS and incubated with ERa primary antibody (sc-542, Santa Cruz Biotechnology) in PBS and 3% BSA overnight at 4uC. Membranes were washed 3 times for 10 minutes in PBS, blocked at room temperature for 1 hour with 5% milk in PBS, and incubated in HRP-conjugated secondary antibodies. Immunoreactive bands were visualized using Western Lightning Plus-ECL (Perkin-Elmer). 
Supporting Information
